A: Jonas Busch
Chefarzt: Klinik für Urologie, Vivantes Klinikum Am Urban

Prof. Dr. Jonas Busch

Schwerpunkte

Expertise

  • jahrelange operative Erfahrungen im Bereich Prostatakarzinom, Nierenzellkarzinom, Hodenkarzinom und Blasenkarzinom
  • Zahlreiche wissenschaftliche Publikationen und Forschungspreise vor allem auf dem Gebiet des Prostatakarzinoms und Nierenzellkarzinoms
  • Mitglieder der interdisziplinären Arbeitsgruppen Nierentumore (IAGN) und Hodentumore (GTSCC) sowie Arbeitsgruppenleiter bei der Erstellung der neuen S3-Leitlinie Hodentumore
  • Gutachter für nationale und internationale wissenschaftliche Fachzeitschriften
  • Mitglied der Berliner (BUG), Deutschen (DGU), Europäischen (EAU) und Amerikanischen Gesellschaft für Urologie (AUA) sowie der Deutschen Krebsgesellschaft (DKG)


Klinische Schwerpunkte

  • Prostatakarzinom: offen chirurgische und robotische (daVinci) nerverhaltende radikale Prostatektomie
  • Nierenzellkarzinom: offen chirurgische und robotische (daVinci) Nierenteilresektion bzw. radikale Nephrektomie mit Cavazapfen-Entfernung
  • Blasenkarzinom: offen chirurgische und robotische (daVinci) nerverhaltende radikale Zystektomie mit Harnableitung (Neoblase oder Ileum Konduit)
  • Hodentumore:  offen chirurgische und robotische (daVinci) Residualtumorresektion
  • Medikamentöse Therapie des metastasierten Nierenzellkarzinoms, Urothelkarzinoms, Prostatakarzinoms und Hodentumoren.


Wissenschaftliche Schwerpunkte

  • Outcome Research mit Vergleich operativer Verfahren und Komplikationen
  • Grundlagen des Nierenzellkarzinoms
  • Klinische Studien zur Therapie metastasierten Nierenzellkarzinom
     

Ich freue mich darauf, gemeinsam mit dem Team der Urologie den uro-onkologischen Schwerpunkt der Klinik weiter auszubauen. Wir wollen unseren Patienten eine moderne Medizin anbieten, wie wir sie uns oder unsere engsten Angehörigen wünschen.

Prof. Dr. Jonas Busch

Vita

  • Studium der Humanmedizin an der Charité Berlin mit Studienaufenthalten in Kalkutta (Indien), Lausanne (Schweiz) und Houston (USA) sowie Promotion in Berlin
  • Facharztausbildung für Urologie an der Charité Universitätsmedizin Berlin
  • 2008 - 2013 Assistenzarzt Klinik für Urologie Charité Berlin mit dem klinischen und wissenschaftlichen Schwerpunkt der Diagnostik und Therapie des Nierenzell- und Prostatakarzinoms
  • 2013 - Klinische und wissenschaftliche Spezialisierung auf dem Gebiet des Prostatakarzinoms an der Stanford University (USA)
  • 2014 Habilitation im Fach Urologie zum Thema „Sequenztherapie beim metastasierten Nierenzellkarzinom“
  • 2015-2016 Kongresssekretär des 68. Jahreskongresses der Deutschen Gesellschaft für Urologie, Programmkommission
  • Seit 2016 Leitender Oberarzt der Charité Klinik für Urologie, Campus Mitte
  • 2016-2018 Leiter des interdisziplinären Prostatakarzinomzentrums der Charité
  • Seit 2019 Stellvertretender Klinikdirektor der Klinik für Urologie
  • 2020 Ernennung zum außerplanmäßigen Professor
     

Publikationen

Originalarbeiten als Erst- oder Letztautor

1.    Busch J, Röllig C, Weißbach L, Kempkensteffen K, Hinz S, Jahnke C, Schostak M, Lein M, Weikert S, Stephan C, Deger S, Ollenschläger G, Miller K, Schrader M.
Entscheidend ist, was ankommt – urologische Leitlinien aus Sicht der Zielgruppe. Urologe 2009; 49:75–80.

2.    Busch J, Röllig C, Weißbach L, Jahnke C, Kempkensteffen C, Hinz S, Schostak M,  Stephan C, Weikert S,  Ollenschläger G, Miller K, Schrader M.
Use of national and international guidelines by German urologists – results of a survey. European Journal of Integrative Medicine 2010;2:129–33.

3.    Busch J, Seidel C, Weikert C, Kempkensteffen C, Wolff I, Weinkauf L, Hinz S, Magheli A, Miller K, Grünwald V.
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
BMC Cancer. 2011 Jul 14;11:295.

4.    Busch J, Hinz S, Kempkensteffen C, Klopf C, Weikert S, Miller K, Magheli A.
Selective lymph node dissection for hormone-refractory prostate cancer after radical prostatectomy. Urol Int. 2012;88(4):441-6. doi: 10.1159/000335206. Epub 2012 Mar 7

5.    Busch J, Seidel C, Kempkensteffen C, Johannsen M, Wolff I, Hinz S, Magheli A, Miller K, Grünwald V, Weikert S.
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol. 2011 Dec;60(6):1163-70. Epub 2011 Jul 21.

6.    Seidel C*, Busch J* ,  Weikert S, Steffens S, Fenner M, Ganser A, Grünwald V. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma. Eur J Cancer. 2012 May;48(7):1023-30. Epub 2012 Mar 20

7.    Busch J, Stephan C, Herold A, Erber B, Kempkensteffen C, Hinz S, Weikert S, Miller K, Magheli A.
Long term oncological and continence outcome following laparoscopic radical prostatectomy – a single center experience. BJU Int. 2012 Dec;110(11 Pt C):E985-90. doi: 10.1111/j.1464-410X.2012.11279.x. Epub 2012 Jun 6.

8.    Busch J, Stephan C, Klutzny A, Hinz S, Kempkensteffen C, Kilic E, Weikert S, Miller K, Magheli A.
Impact of positive surgical margins on oncological outcome following laparoscopic radical prostatectomy (LRP) – long term results. World J Urol. 2013 Apr;31(2):395-401. doi: 10.1007/s00345-012-0866-5. Epub 2012 May 11

9.    Busch J, Erber B, Friedersdorff F, Hoffmann I, Magheli A, Kempkensteffen C, Weikert S, Miller K, Hinz S.
Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer – a single center analysis. BMC Urol. 2012 May 31;12:15. doi: 10.1186/1471-2490-12-15.

10.    Busch J, Hamborg K, Meyer H-A, Buckendahl J, Magheli A, Lein M, Jung K, Miller K, Stephan C.
Value of PSA density and percent free PSA for prostate cancer prognosis. J Urol. 2012 Dec;188(6):2165-70. doi: 10.1016/j.juro.2012.07.106. Epub 2012 Oct 18.

11.    Busch J, Seidel C, Erber B, Issever AS, Hinz S, Kempkensteffen C, Magheli A, Miller K, Grünwald V, Weikert S.
Retrospective Comparison of Triple-sequence Therapies in Metastatic Renal Cell Carcinoma. Eur Urol. 2013 Jul;64(1):62-70. doi: 10.1016/j.eururo.2012.09.004. Epub 2012 Sep 11.

12.    Busch J, Magheli A, Leva N, Hinz S, Ferrari M, Friedersdorff F, Fuller TF, Miller K, Gonzalgo ML. Matched comparison of outcomes following open and minimally invasive radical prostatectomy for high-risk patients. World J Urol. 2014 Dec;32(6):1411-6. doi: 10.1007/s00345-014-1270-0. Epub 2014 Mar 9.
2.Quartil Urologie/Nephrologie; Rang 22/76
    2,981
13.    Busch J, Gonzalgo ML, Leva N, Ferrari M, Cash H, Kempkensteffen C, Hinz S, Miller K, Magheli A. Matched comparison of robot-assisted, laparoscopic and open radical prostatectomy regarding pathologic and oncologic outcomes in obese patients. World J Urol. 2015 Mar;33(3):397-402. doi: 10.1007/s00345-014-1326-1. Epub 2014 May 23.
2.Quartil Urologie/Nephrologie; Rang 22/76
    2,981
14.    Ralla B, Erber B, Goranova I, von der Aue L, Floercken A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J. Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis. World J Urol. 2016 Aug;34(8):1147-54. doi: 10.1007/s00345-015-1740-z. Epub 2015 Dec 16
2.Quartil Urologie/Nephrologie; Rang 22/76
    2,981
15.    Maxeiner A, Magheli A, Jöhrens K, Kilic E, Braun TL, Kempkensteffen C, Hinz S, Stephan C, Miller K, Busch J. Significant reduction in positive surgical margin rate after laparoscopic radical prostatectomy by application of the modified surgical margin recommendations of the 2009 International Society of Urological Pathology consensus. BJU Int. 2016 Nov;118(5):750-757. doi: 10.1111/bju.13451. Epub 2016 Mar 19
1.Quartil Urologie/Nephrologie; Rang 9/76
    4,387
16.    Ralla B, Erber B, Goranova I, von der Aue L, Floercken A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J. Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis. World J Urol. 2016 Aug;34(8):1147-54. doi: 10.1007/s00345-015-1740-z. Epub 2015 Dec 16.
2.Quartil Urologie/Nephrologie; Rang 22/76
    2,981
17.    Busch J, Magheli A, Leva N, Ferrari M, Kramer J, Klopf C, Kempkensteffen C, Miller K, Brooks JD, Gonzalgo ML.
Higher rates of upgrading and upstaging in older patients undergoing radical prostatectomy and qualifying for active surveillance. BJU Int. 2014 Oct;114(4):517-21. doi: 10.1111/bju.12466. Epub 2014 Jan 22.
1.Quartil Urologie/Nephrologie; Rang 9/76

18.    Busch J, Seidel C, Goranova I, Erber B, Peters R, Friedersdorff F, Magheli A, Miller K, Grünwald V, Weikert S. Categories of response to first line vascular endothelial growth factor receptor targeted therapy and overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer. 2014 Feb;50(3):563-9. doi: 10.1016/j.ejca.2013.10.017. Epub 2013 Nov 13.
1.Quartil Onkologie; Rang 25/222

19.    Magheli A*, Busch J*, Leva N, Schrader M, Deger S, Miller K, Lein M. Comparison of surgical technique (open vs. laparoscopic) on pathological and long term functional outcomes following radical prostatectomy. BMC Urol. 2014 Feb 7;14:18. doi: 10.1186/1471-2490-14-18.
3.Quartil Urologie/Nephrologie; Rang 49/76

20.    Hu XH, Cammann H, Meyer HA, Jung K, Lu HB, Leva N, Magheli A, Stephan C, Busch J. Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score. Asian J Androl. 2014 Nov-Dec;16(6):897-901. doi: 10.4103/1008-682X.129940.
1.Quartil Andrologie; Rang 1/5

21.    Busch J, Gonzalgo M, Leva N, Ferrari M, Friedersdorff F, Hinz S, Kempkensteffen C, Miller K, Magheli A. [Propensity score comparison of the various radical surgical techniques for high-risk prostate cancer]. Aktuelle Urol. 2015 Jan;46(1):45-51. doi: 10.1055/s-0034-1395562. Epub 2014 Dec 19. German.
4.Quartil Urologie/Nephrologie; Rang 75/76

22.
    Busch J, Ralla B, Jung M, Wotschofsky Z, Trujillo-Arribas E, Schwabe P, Kilic E, Fendler A, Jung K. Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas. J Exp Clin Cancer Res. 2015 Jun 14;34:61. doi: 10.1186/s13046-015-0180-3.
1.Quartil Onkologie; Rang 33/222

23.     Maxeiner A, Kilic E, Matalon J, Friedersdorff F, Miller K, Jung K, Stephan C, Busch J The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients.. Oncotarget. 2017 Apr 27. doi: 10.18632/oncotarget.17476. [Epub ahead of print]
1.Quartil Onkologie; Rang 50/222

24.     Ralla B, Magheli A, Wolff I, Erber B, Goranova I, Friedersdorff F, Hinz S, Kempkensteffen C, Miller K, Busch J. Prevalence of Late-Onset Hypogonadism in Men with Localized and Metastatic Renal Cell Carcinoma. Urol Int. 2017;98(2):191-197. doi: 10.1159/000450652. Epub 2016 Oct 13.
3.Quartil Urologie/Nephrologie; Rang 54/76

25.    Ralla B, Erber B, Goranova I, Klooker A, Maxeiner A, Hinz S, Kempkensteffen C, Magheli A, Miller K, Busch J. Retrospective Analysis of Fifth-Line Targeted Therapy Efficacy in Patients with Metastatic Renal Cell Carcinoma. Urol Int. 2017;98(2):184-190. doi: 10.1159/000444764. Epub 2016 Mar 11.
3.Quartil Urologie/Nephrologie; Rang 54/76

26.    Maxeiner A, Kilic E, Matalon J, Friedersdorff F, Miller K, Jung K, Stephan C, Busch J. The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients. Oncotarget. 2017 Apr 27;8(45):79279-79288. doi: 10.18632/oncotarget.17476. eCollection 2017 Oct 3.
1.Quartil Onkologie; Rang 50/222

27.    Ralla B, Goranova I, Börnstein N, Friedersdorff F, Maxeiner A, Magheli A, Hinz S, Neymeyer J, Miller K, Busch J. Complications, functional and quality of life outcomes following primary and secondary implantation of penile prosthesis at a tertiary referral center. Int J Impot Res. 2018 Apr;30(2):49-53. doi: 10.1038/s41443-017-0005-3. Epub 2017 Dec 4.
3.Quartil Urologie/Nephrologie; Rang 53/76

28.     Ralla B, Buhl S, Goranova I, Maxeiner A, Friedersdorff F, Magheli A, Hinz S, Fuller TF, Miller K, Busch J. [A retrospective analysis of functional and oncologic outcomes following surgical treatment of patients with pT1/pT2 renal cell carcinoma at a tertiary referral centre]. Aktuelle Urol. 2017 Dec 19. doi: 10.1055/s-0043-118799. [Epub ahead of print] German.
4.Quartil Urologie/Nephrologie; Rang 75/76

29.    Ralla B, Buhl S, Goranova I, Pohle M, Maxeiner A, Friedersdorff F, Magheli A, Hinz S, Fuller TF, Miller K, Busch J. [The use of partial nephrectomy in the treatment of patients with pT1/pT2 renal cell carcinoma: a trend analysis from a tertiary referral centre]. Aktuelle Urol. 2018 Jun;49(3):250-255. doi: 10.1055/s-0043-118791. Epub 2017 Nov 16. German.
4.Quartil Urologie/Nephrologie; Rang 75/76

30.    Busch J, Ralla B, Flörcken A, Westermann J, Zhao Z, Kilic E, Weickmann S, Jung M, Fendler A, Jung K. miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. Cancers (Basel). 2018 Sep 10;10(9). pii: E321. doi: 10.3390/cancers10090321.
1.Quartil Onkologie; Rang 44/222

31    Ralla B , Adams L , Maxeiner A, Mang J, Krimphove M, Dushe S, Makowski M, Miller K, Fuller F, Busch J. Perioperative and oncologic outcome in patients treated for renal cell carcinoma with an extended inferior vena cava tumour thrombus level II-IV. Aktuelle Urol. 2019 Jun 4.  doi: 10.1055/a-0919-4043. 

32    Maxeiner A, Grevendieck A, Pross T, Rudl M, Arnold A, Stephan C, Jung K, Miller K, Kilic E, Busch J. Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer. Aktuelle Urol2019 Dec;50(6):612-618.  doi: 10.1055/a-0856-6545.  Epub 2019 Mar 21.

33.    Ralla B, Buhl S, Goranova I, Pohle M, Maxeiner A, Friedersdorff F, Magheli A, Hinz S, Fuller TF, Miller K, Busch J. Peri- und postoperatives Ergebnis nach Nierentumorchirurgie bei pT1/pT2-Nierenzellkarzinom – eine retrospektive Zentrumsanalyse der funktionellen und onkologischen Ergebnisse. TumorDiagnostik & Therapie 2020; 41(06): 384-392

34.    Friedersdorff  F, Buckendahl  L, Alt  L, Maxeiner  A, Hinz  S, Bichmann  A, Miller K, Magheli A, Busch J. Analysis of quality of life and late biochemical predictors for localized cancer recurrence following radical prostatectomy. World J Urol. 2020 Jun;38(6):1501-1507.  doi: 10.1007/s00345-019-02921-5.  Epub 2019 Aug 28.

Originalarbeiten als Ko-Autor

1.    Wagner M, Rief M, Busch J, Scheurig C, Taupitz M, Hamm B, Franiel T.
Effect of butylscopolamine on image quality in MRI of the prostate. Clinical Radiology 2010;65:460–464.

2.    Grünwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, Reuter C, Ganser A, Johannsen  M.
Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie. 2011;34(6):310-4.

3.    Weikert S, Kempkensteffen C, Johannsen M, Grünwald V,  Zimmermann K, Flörcken A, Westermann J, Busch J, Weinkauf L, Miller K, Keilholz U.
Sequential use of temsirolimus in patients with metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.  World J Urol. 2013 Aug;31(4):805-9. doi: 10.1007/s00345-011-0676-1. Epub 2011 Apr 22.

4.    Wotschofsky Z, Meyer HA, Jung M, Fendler A, Wagner I, Stephan C, Busch J, Erbersdobler A, Disch AC, Mollenkopf HJ, Jung K.
Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem. 2011 Oct 15;417(2):233-41. Epub 2011 Jun 13.

5.    Weikert S, Baumunk D, Stephan C, Cash H, Jahnke, K, Steiner U, Werthemann P, Kempkensteffen C, Magheli A, Hinz S, Jagota A, Busch J, Klopf C, Miller K, Schostak M.
Die Etablierung von interdisziplinären Prostatakrebszentren nach den Empfehlungen der DKG: Eine Kosten-Nutzen-Analyse 3 Jahre nach Zertifizierung. Urologe A. 2011 Sep;50(9):1083-8.

6.    Grünwald V, Seidel C, Fenner M, Ganser A, Busch J, Weikert S.
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer. 2011 Nov 22;105(11):1635-9.

7.    Winter C, Pfister D, Busch J, Bingöl C, Ranft U, Schrader M, Dieckmann KP, Heidenreich A, Albers P.
Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol. 2012 Feb;61(2):403-9. Epub 2011 Nov 7.

8.    Wotschofsky Z, Liep J, Meyer HA, Jung M, Wagner I, Disch AC, Schaser KD, Melcher I, Kilic E, Busch J, Weikert S, Miller K, Erbersdobler A, Mollenkopf HJ, Jung K. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas.  Int J Biol Sci. 2012;8(10):1363-74. doi: 10.7150/ijbs.5106. Epub 2012 Oct 28

9.    Sendeski MM, Persson AB, Liu ZZ, Busch JF, Weikert S, Persson PB, Hippenstiel S, Patzak A.
Iodinated contrast media cause endothelial damage leading to vasoconstriction of human and rat vasa recta. Am J Physiol Renal Physiol. 2012 Dec 15;303(12):F1592-8. doi: 10.1152/ajprenal.00471.2012. Epub 2012 Oct 17.

10.    Friedersdorff F, Roller C, Klein G, Werthemann P, Cash H, Budde K, Slowinski T, Kempkensteffen C, Busch J, Fuller TF, Giessing M.
Outcome of expanded criteria donor kidneys that were transplanted at other Eurotransplant centers after being rejected by our institution. World J Urol. 2013 Aug;31(4):947-52. doi: 10.1007/s00345-012-0929-7. Epub 2012 Aug 18.

11.    Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C.
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol. 2013 Apr;24(4):878-88. doi: 10.1093/annonc/mds579. Epub 2012 Nov 14.

12.    Friedersdorff F, Aghdassi SJ, Werthemann P, Cash H, Goranova I, Busch JF, Ebbing J, Hinz S, Miller K, Neymeyer J, Fuller TF. Laparoendoscopic single-site (LESS) varicocelectomy with reusable components: comparison with the conventional laparoscopic technique. Surg Endosc. 2013 Apr 3. [Epub ahead of print]

13.    Sendeski MM, Liu ZZ, Perlewitz A, Busch JF, Ikromov O, Weikert S, Persson PB, Patzak A. Functional characterization of isolated, perfused outermedullary descending human vasa recta. Acta Physiol (Oxf). 2013 May;208(1):50-6. doi: 10.1111/apha.12084. Epub 2013 Mar 11.

14.    Wotschofsky Z, Busch J, Jung M, Kempkensteffen C, Weikert S, Schaser KD, Melcher I, Kilic E, Miller K, Kristiansen G, Erbersdobler A, Jung K.
Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin Chim Acta. 2013 Feb 1;416:5-10. doi: 10.1016/j.cca.2012.11.010. Epub 2012 Nov 21.

15.    Friedersdorff F, Roller C, Manus P, Cash H, Stier K, Schmidt D, Budde K, Kemkensteffen C, Busch J, Fuller TF, Giessing M. Fate of finally transplanted deceased donor kidneys initially rejected at other kidney transplantation centers. Urol Int. 2014;93(4):474-81. doi: 10.1159/000360302. Epub 2014 Aug 22.

16.    Friedersdorff F, Aghdassi SJ, Magheli A, Richter M, Stephan C, Busch J, Boehmer D, Miller K, Fuller TF. Staging lymphadenectomy in patients with localized high risk prostate cancer: comparison of the laparoendoscopic single site (LESS) technique with conventional multiport laparoscopy. BMC Urol. 2014 Nov 21;14:92. doi: 10.1186/1471-2490-14-92.

17.    Ahdoot M, Almario L, Araya H, Busch J, Conti S, Gonzalgo ML. Oncologic outcomes between open and robotic-assisted radical cystectomy: a propensity score matched analysis. World J Urol. 2014 Dec;32(6):1441-6. doi: 10.1007/s00345-014-1242-4. Epub 2014 Jan 28.

18.    Ivanyi P, Koenig J, Trummer A, Busch JF, Seidel C, Reuter CW, Ganser A, Grünwald V. Does the onset of bone metastasis occurrence in sunitinib treated renal cell carcinoma patients impact the overall survival? World J Urol. 2016 Jul;34(7):909-15. doi: 10.1007/s00345-015-1707-0. Epub 2015 Nov 19.

19.    Lu H, Busch J, Jung M, Rabenhorst S, Ralla B, Kilic E, Mergemeier S, Budach N, Fendler A, Jung K. Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. Clin Chim Acta. 2016 Jan 15;452:109-19. doi: 10.1016/j.cca.2015.11.009. Epub 2015 Nov 10.

20.    Stephan C, Lein M, Matalon J, Kilic E, Zhao Z, Busch J, Jung K. Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index. J Urol. 2016 Sep;196(3):709-14. doi: 10.1016/j.juro.2016.03.009. Epub 2016 Mar 11.

21.    Borgmann H, Salem J, Cebulla A, Ralla B, Busch J, Miller K. [German Society of Urology harnesses social media : Hands-on, interaction, and discussions at the annual meeting]. Urologe A. 2016 Jul;55(7):966-7. doi: 10.1007/s00120-016-0153-y. German. No abstract available.

22.    Friedersdorff F, Patabendhi S, Busch J, Kempkensteffen C, Halleck F, Fuller TF, Miller K, Peters R. Outcome of Patients after Third and Fourth Kidney Transplantation. Urol Int. 2016;97(4):445-449. Epub 2016 Jun 17.

23.    Liep J, Kilic E, Meyer HA, Busch J, Jung K, Rabien A. Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma. PLoS One. 2016 Jun 23;11(6):e0157801. doi: 10.1371/journal.pone.0157801. eCollection 2016.

24.    Friedersdorff F, Kothmann L, Manus P, Roigas J, Kempkensteffen C, Magheli A, Busch J, Liefeldt L, Giessing M, Deger S, Schostak M, Miller K, Fuller TF. Long-Term Donor Outcomes after Pure Laparoscopic versus Open Living Donor Nephrectomy: Focus on Pregnancy Rates, Hypertension and Quality of Life. Urol Int. 2016;97(4):450-456. Epub 2016 Aug 30.

25.    Friedersdorff F, El-Bandar N, Busch J, Erber B, Miller K, Fuller TF, Miller K. Urolithiasis in Renal Allografts: Complications and Outcomes. Exp Clin Transplant. 2017 Apr;15(2):164-170. doi: 10.6002/ect.2016.0040. Epub 2016 Nov 18.

26.    Pohle M, Magheli A, Fischer T, Kempkensteffen C, Busch J, Cash H, Miller K, Hinz S. The Effect of Evolving Strategies in the Surgical Management of Organ-Confined Prostate Cancer: Comparison of Data from 2005 to 2014 in a Multicenter Setting. Adv Ther. 2017 Feb;34(2):576-585. doi: 10.1007/s12325-016-0469-4. Epub 2017 Jan 4.

27.    Friedersdorff F, Groß B, Maxeiner A, Jung K, Miller K, Stephan C, Busch J, Kilic E. Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy. Int J Mol Sci. 2017 Feb 24;18(3). pii: E488. doi: 10.3390/ijms18030488.

28.    Spatz S, Tolkach Y, Jung K, Stephan C, Busch J, Ralla B, Rabien A, Feldmann G, Brossart P, Bundschuh RA, Ahmadzadehfar H, Essler M, Toma M, Müller SC, Ellinger J, Hauser S, Kristiansen G. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role. J Urol. 2018 Feb;199(2):370-377. doi: 10.1016/j.juro.2017.08.079. Epub 2017 Aug 19.

29.    Kürschner G, Zhang Q, Clima R, Xiao Y, Busch JF, Kilic E, Jung K, Berndt N, Bulik S, Holzhütter HG, Gasparre G, Attimonelli M, Babu M, Meierhofer D. Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione. Oncotarget. 2017 Nov 11;8(62):105882-105904. doi: 10.18632/oncotarget.22413. eCollection 2017 Dec 1.

30.    Reimann M, Fishman N, Almedom Z, Lichy I, Buckendahl J, Steiner U, Friedersdorff F, Busch J, Fuller TF, Miller K, Hinz S, Cash H. Perioperative Changes and Progress in Photoselective Vaporization of the Prostate with GreenLight XPS 180 W System: A Single Center Experience. Urol Int. 2018;100(4):463-469. doi: 10.1159/000487958. Epub 2018 Apr 5.

31.    Adams LC, Ralla B, Bender YY, Bressem K, Hamm B, Busch J, Fuller F, Makowski MR. Renal cell carcinoma with venous extension: prediction of inferior vena cava wall invasion by MRI. Cancer Imaging. 2018 May 3;18(1):17. doi: 10.1186/s40644-018-0150-z.

32.    Adams LC, Ralla B, Engel G, Diederichs G, Hamm B, Busch J, Fuller F, Makowski MR. Assessing venous thrombus in renal cell carcinoma: preliminary results for unenhanced 3D-SSFP MRI. Clin Radiol. 2018 Aug;73(8):757.e9-757.e19. doi: 10.1016/j.crad.2018.04.003. Epub 2018 May 17.

33.    Adams LC, Ralla B, Jurmeister P, Bressem KK, Fahlenkamp UL, Hamm B, Busch J, Makowski MR. Native T1 Mapping as an In Vivo Biomarker for the Identification of Higher-Grade Renal Cell Carcinoma: Correlation With Histopathological Findings. Invest Radiol. 2018 Oct 30. doi: 10.1097/RLI.0000000000000515.

34.    Ebbing J, Heckmann RC, Collins JW, Miller K, Erber B, Friedersdorff F, Fuller TF, Busch J, Seifert HH, Ardelt P, Wetterauer C, Hosseini A, Jentzmik F, Kempkensteffen C. Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer. Sci Rep2018 May 30;8(1):8360.  doi: 10.1038/s41598-018-26089-x.

35.    Paffenholz P, Pfister P, Busch J, Dieckmann KP, Schmelz HU, Heidenreich A. Management of growing teratoma syndrome (GTS): Results of the German Testicular Cancer Study Group. Journal of Clinical Oncology 36, no. 6_suppl (February 20, 2018) 566-566.

36.    Ebbing E, Menzel F, Frumento P, Miller K, Ralla B, Fuller TF, Busch J, Collins JW, Adding C, Seifert HH, Ardelt P, Wetterauer C, Westhoff T, Kempkensteffen C. Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer. BMC Nephrol. 2019 Feb 4;20(1):40. doi: 10.1186/s12882-019-1215-3.

37.    Collettini F, Enders J, Stephan C, Fischer T, Baur ADJ, Penzkofer T, Busch J, Hamm B, Gebauer B. Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes. Radiology. 2019 Jul;292(1):250-257. doi: 10.1148/radiol.2019181987. Epub 2019 Jun 4.

38.    Al Ahmad A, Paffrath V, Clima R, Busch JF, Rabien A, Kilic E, Villegas S, Timmermann B, Attimonelli M, Jung K, Meierhofer D. Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation. Cancers (Basel) 2019 Sep 3;11(9):1298.  doi: 10.3390/cancers11091298.

39.    Ullah I, Abu-Dawud R, Busch JF, Rabien A, Erguen B, Fischer I, Reinke P, Kurtz A. VEGF - Supplemented extracellular matrix is sufficient to induce endothelial differentiation of human iPSC. Biomaterials. 2019 Sep;216:119283. doi: 10.1016/j.biomaterials.2019.119283. Epub 2019 Jun 18.

40.    Adams L, Jurmeister P, Ralla B, Bressem KK, Fahlenkamp UL, Engel G, Siepmann S, Wagner M, Hamm B, Busch J, Makowski M. Assessment of the extracellular volume fraction for the grading of clear cell renal cell carcinoma: first results and histopathological findings. Radiol2019 Nov;29(11):5832-5843.  doi: 10.1007/s00330-019-06087-x.  Epub 2019 Mar 18.

41.    Fendler A, Bauer D, Busch J, Jung K, Wulf-Goldenberg A, Kunz S, Song K, Myszczyszyn A, Elezkurtaj S, Erguen B, Jung S, Chen W, Birchmeier W. Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun. 2020 Feb 17;11(1):929. doi: 10.1038/s41467-020-14700-7.

42.    Xiao Y, Clima R, Busch J, Rabien A, Kilic E, Villegas S, Timmermann, T Attimonelli M, Jung K, Meierhofer D. Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma. Cancer Res 2020 Sep 15;80(18):3830-3840.  doi: 10.1158/0008-5472.CAN-20-0754. Epub 2020 Jul 21.

43.    Kalogirou C, Ellinger J, Kristiansen G, Hatzichristodoulou G, Kübler H, Kneitz B, Busch J, Fendler A. Identification of miR-21-5p and miR-210-3p serum levels as biomarkers for patients with papillary renal cell carcinoma: a multicenter analysis. Transl Androl Urol 2020 Jun;9(3):1314-1322.  doi: 10.21037/tau.2020.03.18.

44.    Simonovic S, Hinze C, Schmidt-Ott K, Busch J, Jung M, Jung K, Rabien A. Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients. BMC Urol 2020 Feb 4;20(1):7.  doi: 10.1186/s12894-019-0542-9.

45.    Ullah I,  Busch JF,  Rabien A, Ergün B, Stamm C, Knosalla C, Hippenstiel S, Reinke P, Kurtz A. Adult Tissue Extracellular Matrix Determines Tissue Specification of Human iPSC‐Derived Embryonic Stage Mesodermal Precursor Cells. Adv Sci (Weinh) 2020 Jan 21;7(5):1901198.  doi: 10.1002/advs.201901198.  eCollection 2020 Mar.

46.    Maxeiner A, Nest AM, Stephan C, Cash H, Baur A,  Fischer T, Kilic E, Piper S, Nowak C, Busch J, Miller K, Mang J. Additive Value of Transrectal Systematic Ventral Biopsies in Combination with Magnet Resonance Imaging/Ultrasound Fusion-Guided Biopsy in Patients with 3 or More Negative Prostate Biopsies. Urol Int 2020;104(3-4):205-213.  doi: 10.1159/000504266.  Epub 2019 Dec 4.

47.    Goebell PJ, Ivanyi P, Bedke J, Bergmann L, Berthold D, Boegemann M, Busch J, Doehn C, Krege S, Retz M, Amsberg GV, Grimm MO, Gruenwald V.
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma. Future Oncol. 2020 Oct;16(29):2307-2328. doi: 10.2217/fon-2020-0403. Epub 2020 Sep 23.

48.    Köhler N, El-Bandar N, Maxeiner A, Ralla B, Miller K, Busch J, Friedersdorff F. Early Continence and Extravasation After Open Retropubic Radical Prostatectomy - Interrupted vs Continuous Suturing for Vesicourethral Anastomosis. Ther Clin Risk Manag. 2020 Dec 23;16:1289-1296. doi: 10.2147/TCRM.S278454. eCollection 2020.PMID: 33380800

49.    Xiao Y, Rabien A, Buschow R, Amtislavskiy V, Busch J, Kilic E, Villegas SL, Timmermann B, Schütte M, Mielke T, Yaspo ML, Jung K, Meierhofer D. Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma. Cancer Res. 2020 Dec 15;80(24):5491-5501. doi: 10.1158/0008-5472.CAN-20-1998. Epub 2020 Oct 28.

Übersichtsarbeiten

1.    Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol 2010;7:286-97
2.    Zengerling F, Schrader M, Busch J. Aktuell Therapie des Seminoms. Spectrum Urologie 03/2014
3.    Busch J, Hinz S, Zengerling F. Nichtseminom – Aktuelle Therapie mit Fokus auf Stadium I. Spectrum Urologie 03/2014
4.    Busch J, Erber B, Magheli A, Miller K. Metastasiertes Nierenzellkarzinom – Status der Therapie 2015. Ärzteblatt 2015
5.    Busch J, Seidel C, Zengerling F. Male extragonadal germ cell tumors of the adult. Oncol Res Treat 2016;39:140-144

Editorials/Comments/Letters to the editor:

1.    Busch J, Magheli A, Miller K. Vielversprechende Ergebnisse. Comment in Aktuel Urol 2011;42:275-276

2.    Busch J. Vorwort zu Fokus Hodenkarzinom in Spectrum Urologie 03/2014

3.    Busch J. Evidenz in der Breite. Editorial zur Übersichtsarbeit:
Zengerling F et al. Nationales Zweitmeinungsnetzwerk Hodentumoren – ein System zum Evidenztransport
Aktuel Urol 2014; 45(06): 454-456 DOI: 10.1055/s-0034-1395624

4.    Busch J. [Selection procedure for scientific contributions to the German Society of Urology (DGU) congress 2016]. Urologe A. 2016 Sep;55 Suppl 1:2-4. doi: 10.1007/s00120-016-0212-4. German.

5.    Stephan C, Busch J, Jung K. The value of digital rectal examination in clinical practice. AME Med J 2018;3:45

6.    Ullah I, Abu-Dawud R, Busch JF, Rabien A, Erguen B, Fischer I, Reinke P, Kurtz A. Corrigendum to “VEGF – Supplemented extracellular matrix is sufficient to induce endothelial differentiation of human iPSC” [Biomaterials 216 (2019) 119283 1–10]

7.    Ebbing E, Menzel F, Frumento P, Miller K, Ralla B, Fuller TF, Busch J, Collins JW, Adding C, Seifert HH, Ardelt P, Wetterauer C, Westhoff T, Kempkensteffen C. Correction to: Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancer. BMC Nephrol2019 Mar 7;20(1):86.  doi: 10.1186/s12882-019-1264-7.


Buchkapitel:

1.    Busch J und Seidel C. Extragonadale Keimzelltumoren. Kapitel 169-1 im Handbuch „Die Urologie“; Springer Verlag, ISBN 978-3-642-39939-8, Erscheinungsdatum 15.11.2015, Aktualisierung 2020
2.    Busch J; Überarbeitung der Deutschen Übersetzung des Kapitels „Hodentumore“ in Harrisons Innere Medizin; 20. Auflage, Thieme Verlag